Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Goodwin Doubles Down On Antitrust, M&A With Another Partner Hire (Reuters)

Related Content

States Continue to Pursue and Expand Healthcare Market Oversight at an Unprecedented Pace, With Significant Implications for Private Equity

FTC’s First Merger Challenge Under New Leadership Signals Return to Traditional Antitrust Theories in Private Equity Deals

Antitrust and Competition Technology Year in Review 2024

Antitrust and Competition Life Sciences Year in Review 2024

How the Trump Administration Could Reshape Regulation in the Life Sciences Sector

DOJ Sues Private Equity Firm KKR & Co. for Violations of HSR Act

Massachusetts Passes Comprehensive Revisions to Healthcare Transaction Notification Law with Significant Implications for Private Equity Healthcare Investments

2025 HSR Thresholds Announced: $126.4 million

Goodwin Bolsters Brussels Offering with Partner Athena Kontosakou and a Team of Global Antitrust and EU Regulatory Experts

Boston Forum: Merger Control & Competition in Life Sciences

Antitrust Considerations for the Pharmaceutical Industry: Pharmacy Benefit Managers (PBMs) and Algorithmic Pricing

ABA Antitrust Spring Meeting

Chambers Europe 2025 Recognizes Goodwin Across Belgium and the United Kingdom

Six Goodwin Lawyers Named to Law360’s 2025 Editorial Advisory Boards

2seventy bio To Be Acquired by Bristol Myers Squibb for $5.00 per Share

Goodwin Hires Antitrust Partner In DC (Law360)

Technology

Life Sciences

Private Equity

Medtech

Antitrust & Competition

Mergers & Acquisitions

Complex Litigation & Dispute Resolution

Antitrust Services for Life Sciences Companies

Litigation